The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Inotuzumab ozogamicin (IO) in combination with low-intensity chemotherapy as front-line therapy for older patients (pts) and as salvage therapy for adult with R/R acute lymphoblastic leukemia (ALL).
Elias Jabbour
No relevant relationships to disclose
Susan Mary O'Brien
No relevant relationships to disclose
Nitin Jain
No relevant relationships to disclose
Deborah A. Thomas
No relevant relationships to disclose
Guillermo Garcia-Manero
No relevant relationships to disclose
Farhad Ravandi
No relevant relationships to disclose
Gautam Borthakur
No relevant relationships to disclose
Sergernne York
No relevant relationships to disclose
Rebecca Garris
No relevant relationships to disclose
Jorge E. Cortes
No relevant relationships to disclose
Hagop M. Kantarjian
Research Funding - Pfizer